Boulder, CO
Viridian Therapeutics, Inc. operates as a biotechnology company. The Company specializes in developing multiple product candidates to treat patients who suffer from thyroid eye disease (TED), a debilitating orphan disease, and has early-stage programs focused on other targets and indications. Viridian Therapeutics serves customers in the United States.
viridiantherapeutics.comEmploybl Premium
Premium profiles, AI research on tech stack and hiring, 61,000+ ATS job listings, saved searches, and an AI chat that knows the SF startup scene.
These are collections Viridian Therapeutics is a part of. Click on the collection name to view similar companies.
6200 Lookout Rd #100, Boulder, CO, 80301-3695
Post Ipo Debt
$225,000,000
Post Ipo Equity
$125,000,014
Post Ipo Equity
$289,000,000
Post Ipo Debt
$55,000,000
Post Ipo Equity
$225,000,000
Post Ipo Equity
$150,000,000
Post Ipo Equity
$185,000,000
Post Ipo Debt
$75,000,000
Post Ipo Equity
$85,000,000
Post Ipo Equity
$90,997,328
Series Unknown
$27,000,000
Seed
$2,000,000
Post Ipo Equity
$1,500,000
Series C
$40,700,000
Series B
$8,500,000
Series B
$7,000,000
IPO
Unknown
Series B
$20,000,000
Convertible Note
$6,000,000
Convertible Note
$25,000,000
Series A
$4,000,000
Series A
$8,000,000
0 out of 5 stars
Based on 0 reviews
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Viridian Therapeutics.